Rankin Aubrey 4
4 · Revance Therapeutics, Inc. · Filed Mar 17, 2022
Insider Transaction Report
Form 4
Rankin Aubrey
DirectorPresident, Innovation & Tech
Transactions
- Tax Payment
Common Stock
2022-03-15$15.79/sh−1,372$21,664→ 94,091 total
Holdings
- 154,302(indirect: By Trust)
Common Stock
- 321,611(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 11,905 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Rankin's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
- [F2]These shares are held by The Rankin Irrevocable Trust. Mr. Rankin is a Trustee of the Rankin Irrevocable Trust.
- [F3]These shares are held by the Aubrey and Luanne Rankin Revocable Living Trust dated July 1, 2009. Mr. Rankin is a Trustee of this Trust.